Last update: Oct. 11, 2017
Minimal risk for breastfeeding and infant.
An antibacterial with very few bibliographical references which is used with little evidence of its efficacy (N.A.L. Prescrire 2004 and 1999) in the treatment of acute gastroenteritis of bacterial origin.
Since the last update we have not found published data about its excretion in breast milk.
It has a very low oral bioavailability, due to low or zero intestinal absorption (Armstrong 2015), making it unlikely its would pass into breast milk.
Its low oral bioavailability would also further complicate its passing into the infant’s plasma via ingested breast milk, except in premature babies and in the immediate neonatal period during which there may be greater intestinal permeability.
We do not have alternatives for Nifuroxazide since it is relatively safe.
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.